These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8946471)
1. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247 [TBL] [Abstract][Full Text] [Related]
3. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816 [TBL] [Abstract][Full Text] [Related]
4. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064 [TBL] [Abstract][Full Text] [Related]
5. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Evert B; Griese EU; Eichelbaum M Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481 [TBL] [Abstract][Full Text] [Related]
6. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism. Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480 [TBL] [Abstract][Full Text] [Related]
7. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
8. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Chida M; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T Pharmacogenetics; 1999 Jun; 9(3):287-93. PubMed ID: 10471060 [TBL] [Abstract][Full Text] [Related]
9. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese]. Yokoi T; Kamataki T Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457 [TBL] [Abstract][Full Text] [Related]
10. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820 [TBL] [Abstract][Full Text] [Related]
11. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268 [TBL] [Abstract][Full Text] [Related]
12. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749 [TBL] [Abstract][Full Text] [Related]
13. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072 [TBL] [Abstract][Full Text] [Related]
14. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150 [TBL] [Abstract][Full Text] [Related]
15. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409 [TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Broly F; Meyer UA Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
18. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152 [TBL] [Abstract][Full Text] [Related]